Bavarian Nordic to Host Third Quarter 2012 Results Conference Call
(Thomson Reuters ONE) -
KVISTGAARD, Denmark - November 5, 2012 - Bavarian Nordic A/S (OMX: BAVA) will
announce its interim financial results for the first nine months of 2012 on
Tuesday, November 13, 2012.
The company will host a conference call at 2:00 pm CET (8:00 am EST) on the same
day. Anders Hedegaard, President and CEO, will give a short presentation
followed by a Q&A session. Additional participants from Bavarian Nordic are Paul
Chaplin, Executive Vice President and Division President Infectious Diseases,
Reiner Laus, Executive Vice President and Division President Cancer Vaccines,
Ole Larsen, Executive Vice President and CFO and Rolf Sass Sørensen, Vice
President Investor Relations.
Dial-in numbers for the conference call are: UK: +44 (0)20 7162 0077. USA:
+1 334 323 6201. Denmark: +45 3271 4607. The participant code is 924959.
For additional details please visit http://www.bavarian-nordic.com/q3 where also
the accompanying presentation will be available in advance of the conference
call.
A recording of the conference call will be available from the company's website
during the same day.
Contact
Rolf Sass Sørensen, Vice President Investor Relations & Communications
E-mail: investor(at)bavarian-nordic.com
Phone: +45 33 26 83 83
About Bavarian Nordic
Bavarian Nordic is a vaccine-focused biotechnology company developing and
producing novel vaccines for the treatment and prevention of life-threatening
diseases with a large unmet medical need. The company's pipeline targets cancer
and infectious diseases, and includes ten development programs. In oncology, the
company's lead program is PROSTVAC®, a therapeutic vaccine candidate for
advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 trial
and is being developed under a collaboration agreement with the National Cancer
Institute. In clinical Phase 1 and Phase 2 trials, PROSTVAC® has been tested in
nearly 600 patients. In infectious diseases, the company's lead program is
IMVAMUNE®, a third-generation smallpox vaccine candidate that is being developed
and supplied for emergency use to the U.S. Strategic National Stockpile under a
contract with the U.S. Government. For more information, visit www.bavarian-
nordic.com.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Bavarian Nordic A/S via Thomson Reuters ONE
[HUG#1655036]
Unternehmensinformation / Kurzprofil:
Datum: 05.11.2012 - 17:30 Uhr
Sprache: Deutsch
News-ID 199679
Anzahl Zeichen: 3014
contact information:
Town:
Kvistgård
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 175 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Bavarian Nordic to Host Third Quarter 2012 Results Conference Call"
steht unter der journalistisch-redaktionellen Verantwortung von
Bavarian Nordic A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
